<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03692520</url>
  </required_header>
  <id_info>
    <org_study_id>SCT200-X101</org_study_id>
    <nct_id>NCT03692520</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>Recombinant Anti-EGFR Monoclonal Antibody（SCT200）in Patients With Advanced Solid Tumors or Lymphoma : A Phase Ⅰb, Open-label, Multicenter Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinocelltech Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinocelltech Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR&#xD;
      monoclonal antibody（SCT200）in patients with advanced solid tumors treated after failure of&#xD;
      standard therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open label, multicenter phase Ib study is designed to evaluate Objective Response Rate&#xD;
      (ORR) in advanced solid tumors (gastric/gastroesophageal junction cancer, hepatocellular&#xD;
      carcinoma,pancreatic cancer,gallbladder cancer/bile duct cancer，renal cell carcinoma，ovarian&#xD;
      cancer，or other advanced solid tumor) treated with anti-EGFR monoclonal antibody SCT200.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">September 30, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>1 year</time_frame>
    <description>ORR is defined as proportion of patients achieving complete response (CR) or partial response (PR) according to RECIST v1.1 during trial treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>1 year</time_frame>
    <description>AE are assessed according to NCI CTCAE v4.03.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progress Free Survival ( PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>PFS is defined as the time from first dose of SCT200 until the date of first documentation of progression or date of death, whichever occurs first,according to RECIST v1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>1 year</time_frame>
    <description>The achievement of any a stable response（SD）, partial response (PR) or complete response (CR), according to RECIST v1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>1 year</time_frame>
    <description>OS is defined as time from first dose of SCT200 until the date of death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>SCT200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SCT200</intervention_name>
    <description>Recombinant Anti-EGFR Monoclonal Antibody （SCT200）</description>
    <arm_group_label>SCT200</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to provide written informed consent and can understand and comply with the&#xD;
             requirements of the study;&#xD;
&#xD;
          -  Males or females. Aged 18 to 75 years old;&#xD;
&#xD;
          -  Life expectancy of longer than 3 months ( clinical assessment);&#xD;
&#xD;
          -  With an Eastern Cooperative Oncology Group (ECOG) performance status 0-1;&#xD;
&#xD;
          -  Histological or cytological diagnosis of advanced solid&#xD;
             tumors(gastric/gastroesophageal junction cancer, hepatocellular carcinoma,pancreatic&#xD;
             cancer,gallbladder cancer/bile duct cancer，renal cell carcinoma，ovarian cancer，other&#xD;
             advanced solid tumor)&#xD;
&#xD;
          -  Advanced solid tumor or lymphoma wuth failure of standard treatment;&#xD;
&#xD;
          -  According to RECIST 1.1 , patients must have at least one measurable lesion that can&#xD;
             be accurately assessed;&#xD;
&#xD;
          -  Adequate organ and marrow function as defined below:&#xD;
&#xD;
        Absolute neutrophil count (ANC) greater than/equal to 1.5×l09/L; Platelets greater&#xD;
        than/equal to 75×109/L; Hemoglobin greater than/equal to 80g/L; Aspartate aminotransferase&#xD;
        (AST)/alanine aminotransferase (ALT) less than/equal to 3 times ULN, or less than/equal to&#xD;
        5 times ULN if known liver metastases; Total bilirubin less than/equal to 1.5 within&#xD;
        institutional limit of normal (ULN); Serum creatinine less than/equal to 1.5 times ULN;&#xD;
        Electrolyte: magnesium greater than/equal to normal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are allergic to analogue of SCT200 and/or its inactive ingredients;&#xD;
&#xD;
          -  Patients with active central nervous system metastasis or a history of central nervous&#xD;
             system metastasis;(If the subject has been suspected with central nervous system&#xD;
             metastasis,imaging examination confirmation must be performed within 28 days to&#xD;
             exclude central nervous system metastasis;&#xD;
&#xD;
          -  Subject receiving bisphosphonate or denosumab treatment for bone metastases was&#xD;
             initiated within 28 days prior to study. (If the subject has received bisphosphonate&#xD;
             or denosumab treatment prior to study and showing stable time at least 28 days,the&#xD;
             subject will be allowed to use it.) Subjects who were enrolled in this study may start&#xD;
             taking bisphosphonate or denosumab for bone metastases after the first assessment of&#xD;
             the efficacy.&#xD;
&#xD;
          -  Patients with other primary malignancies, except cured of basal cell carcinoma skin&#xD;
             cancer, carcinoma in situ of cervix, or prostatic intraepithelial neoplasia;&#xD;
&#xD;
          -  Patients administrated EGFR target treatment including EGFR TKI agent or anti- EGFR&#xD;
             monoclonal antibody;&#xD;
&#xD;
          -  Within 4 weeks, patients received anti-tumor drugs (such as chemotherapy, hormone&#xD;
             therapy, immune therapy, the antibody therapy, radiotherapy) or research drugs, or&#xD;
             patients with grade 2 or more adverse reaction caused by previous anti-tumor&#xD;
             therapy(except alopecia or neurotoxicity grade 2 or less);&#xD;
&#xD;
          -  Patients are currently enrolled in other research devices or in research drugs, or&#xD;
             less than 4 weeks from other research drugs or devices.&#xD;
&#xD;
          -  Prior to the first dose of study drug, patients received major surgery requiring&#xD;
             general anesthesia has been completed less than 4 weeks; surgery requiring local&#xD;
             anesthesia/epidural anesthesia has been completed less than 72 hours; skin biopsy&#xD;
             requiring local anesthesia has been completed less than 1 hour.&#xD;
&#xD;
          -  Patients treated with EPO, G-CSF or GM-CSF.&#xD;
&#xD;
          -  Patients who have clinically significant cardiovascular disease (defined as unstable&#xD;
             angina pectoris, symptomatic congestive heart failure (NYHA, greater than II),&#xD;
             uncontrollable severe arrhythmia);&#xD;
&#xD;
          -  Patients occurred myocardial infarction within 6 months.&#xD;
&#xD;
          -  Patients who have interstitial lung disease, such as interstitial pneumonia, pulmonary&#xD;
             fibrosis, or CT or MRI reminder ILD .&#xD;
&#xD;
          -  Patients with clinical symptoms, required clinical intervention or stable time less&#xD;
             than 4 weeks of serous cavity effusion (such as pleural effusion and ascites);&#xD;
&#xD;
          -  Patients with medical or psychiatric condition or laboratory abnormality may interfere&#xD;
             with the interpretation of study results;&#xD;
&#xD;
          -  Pregnant or lactating women, or women who planned to be pregnant within 6 months of&#xD;
             treatment;&#xD;
&#xD;
          -  Patients who were not willing to accept effective contraceptive measures (including&#xD;
             male or female subjects) during treatment and for at least 6 months after your last&#xD;
             dose of SCT200;&#xD;
&#xD;
          -  Patients with active hepatitis B or active hepatitis C, etc. (for patients with a&#xD;
             history of hepatitis B, whether treated or not, HBV DNA ≥104 or ≥ 2000IU/ml, HCV&#xD;
             RNA≥15IU/ml); HIV antibody positive (if there is no clinical evidence suggesting HIV&#xD;
             infection, there is no need to detect);&#xD;
&#xD;
          -  Patients with uncontrolled active infections within 2 weeks before enrollment (except&#xD;
             urinary tract infection or upper respiratory tract infection);&#xD;
&#xD;
          -  Patients have alcohol or drug addiction;&#xD;
&#xD;
          -  Subjects who are considered unsuitable for participating in this study for various&#xD;
             reasons at the discretion of the investigator，such as inability to comply with study&#xD;
             and/or follow-up procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jianming xu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>307 Hospital of PLA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>307 Hospital of PLA</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>September 29, 2018</study_first_submitted>
  <study_first_submitted_qc>September 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <last_update_submitted>September 29, 2018</last_update_submitted>
  <last_update_submitted_qc>September 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasms</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>Epidermal growth factor receptor</keyword>
  <keyword>EGFR</keyword>
  <keyword>SCT200</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

